Received Nov 10, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | 35A77 | IM / RA |
Numbness injection site to tips of fingers; numbness in his right arm; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of injection site numbness in a 60-year-old male patient who received Herpes zoster (Shingrix) (batch number 35A77, expiry date 04-APR-2027) for prophylaxis. On 02-SEP-2025, the patient received the 1st dose of Shingrix (intramuscular, right arm). On an unknown date, an unknown time after receiving Shingrix, the patient experienced injection site numbness (Verbatim: Numbness injection site to tips of fingers) and numbness (Verbatim: numbness in his right arm). The outcome of the injection site numbness and numbness were not resolved. It was unknown if the reporter considered the injection site numbness and numbness to be related to Shingrix. It was unknown if the company considered the injection site numbness and numbness to be related to Shingrix. Additional Information: GSK Receipt Date: 28-OCT-2025 Pharmacist stated that a patient reported intermittent numbness in his right arm after receiving Shingrix IM on 2-SEP-2025 and that was still ongoing. That was occurring from the injection site to tips of fingers. Patient reported that no pain.